Salvador Perez-Galera
Overview
Explore the profile of Salvador Perez-Galera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou H, Buetti N, Perez-Galera S, Bravo-Ferrer J, Gutierrez-Gutierrez B, Paniagua-Garcia M, et al.
J Antimicrob Chemother
. 2024 Jul;
79(9):2132-2141.
PMID: 38988305
Background: Carbapenem-resistant Enterobacterales (CRE) bloodstream infections (BSIs) are a major threat to patients. To date, data on risk factors have been limited, with low internal and external validity. In this...
2.
Paniagua-Garcia M, Bravo-Ferrer J, Perez-Galera S, Kostyanev T, de Kraker M, Feifel J, et al.
Clin Microbiol Infect
. 2024 Jan;
30(2):223-230.
PMID: 38267096
Objectives: To assess the mortality attributable to infections caused by carbapenem-resistant Enterobacterales (CRE) and to investigate the effect of clinical management on differences in observed outcomes in a multinational matched...
3.
Perez-Galera S, Bravo-Ferrer J, Paniagua M, Kostyanev T, de Kraker M, Feifel J, et al.
EClinicalMedicine
. 2023 Mar;
57:101871.
PMID: 36895801
Background: Data on risk factors for carbapenem-resistant Enterobacterales (CRE) with wider applicability are needed to inform preventive measures and efficient design of randomised trials. Methods: An international matched case-control-control study...
4.
Nunez-Nunez M, Perez-Galera S, Giron-Ortega J, Sandoval Fernandez-Del-Castillo S, Beltran-Garcia M, Cueto M, et al.
Front Pharmacol
. 2022 Oct;
13:1018158.
PMID: 36299899
Antibiotic stewardship programs (ASP) have already demonstrated clinical benefits. We aimed to describe the Point Prevalence Surveys (PPS) methodology implemented in our hospital as an efficient tool to guide ASP...
5.
Gutierrez-Gutierrez B, Perez-Nadales E, Perez-Galera S, Fernandez-Ruiz M, Carratala J, Oriol I, et al.
Antimicrob Agents Chemother
. 2021 Aug;
65(11):e0110221.
PMID: 34370578
There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment...
6.
Gutierrez-Gutierrez B, Morales I, Perez-Galera S, Fernandez-Riejos P, Retamar P, Cueto M, et al.
Diagn Microbiol Infect Dis
. 2018 Aug;
93(1):63-68.
PMID: 30131239
Objective: To investigate whether the magnitude of the change in procalcitonin (PCT) and C-reactive protein (CRP) levels between day 1 and day 2 after the blood culture date is associated...
7.
Gutierrez-Gutierrez B, Perez-Galera S, Salamanca E, Cueto M, Calbo E, Almirante B, et al.
Antimicrob Agents Chemother
. 2016 May;
60(7):4159-69.
PMID: 27139473
The spread of extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) is leading to increased carbapenem consumption. Alternatives to carbapenems need to be investigated. We investigated whether β-lactam/β-lactamase inhibitor (BLBLI) combinations are as effective...